{"name":"Atea Pharmaceuticals","slug":"atea","ticker":"AVIR","exchange":"NASDAQ","domain":"ateapharma.com","description":"Atea Pharmaceuticals (AVIR) is a biotechnology company focused on developing antiviral therapies. The company's top drugs include AT-527, a direct-acting antiviral (DAA) for the treatment of COVID-19. Atea Pharmaceuticals is positioned to capitalize on the growing demand for antiviral treatments. The company's pipeline includes several promising candidates in various stages of development.","hq":"Boston, MA","founded":0,"employees":"","ceo":"Jean-Pierre Sommadossi","sector":"Antiviral Biotech","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"$290M","metrics":{"revenue":351367000,"revenueGrowth":0,"grossMargin":0,"rdSpend":148024000,"netIncome":-158349000,"cash":315218000,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2021"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2030-06-01","label":"AT-527 patent cliff ($0.0B at risk)","drug":"AT-527","type":"patent_expiry","sentiment":"negative"}],"diseaseAreas":[{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":4,"colorKey":"oncology","drugs":[{"name":"AT-527 Formulation 1","genericName":"AT-527 Formulation 1","slug":"at-527-formulation-1","indication":"Other","status":"phase_1"},{"name":"AT-527 Formulation 2","genericName":"AT-527 Formulation 2","slug":"at-527-formulation-2","indication":"Other","status":"phase_1"},{"name":"AT-527 fasted","genericName":"AT-527 fasted","slug":"at-527-fasted","indication":"Other","status":"phase_1"},{"name":"AT-527 fed","genericName":"AT-527 fed","slug":"at-527-fed","indication":"Other","status":"phase_1"}]},{"name":"Infectious Disease","slug":"infectious-disease","revenue":0,"percentOfTotal":0,"drugCount":4,"colorKey":"immunology","drugs":[{"name":"AT-527 and Probenecid","genericName":"AT-527 and Probenecid","slug":"at-527-and-probenecid","indication":"COVID-19","status":"phase_1"},{"name":"AT-527 single dose","genericName":"AT-527 single dose","slug":"at-527-single-dose","indication":"Treatment of SARS-CoV-2 infection","status":"phase_1"},{"name":"Bemnifosbuvir (BEM)","genericName":"Bemnifosbuvir (BEM)","slug":"bemnifosbuvir-bem","indication":"COVID-19 (SARS-CoV-2 infection)","status":"phase_3"},{"name":"Bemnifosbuvir-Ruzasvir","genericName":"Bemnifosbuvir-Ruzasvir","slug":"bemnifosbuvir-ruzasvir","indication":"Chronic hepatitis C virus (HCV) infection, genotype 1-6","status":"phase_3"}]}],"pipeline":[{"name":"AT-527 Formulation 1","genericName":"AT-527 Formulation 1","slug":"at-527-formulation-1","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"AT-527 Formulation 2","genericName":"AT-527 Formulation 2","slug":"at-527-formulation-2","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"AT-527 and Probenecid","genericName":"AT-527 and Probenecid","slug":"at-527-and-probenecid","phase":"phase_1","mechanism":"AT-527 is a nucleoside analog that inhibits the RNA-dependent RNA polymerase of SARS-CoV-2, and Probenecid is a uricosuric agent that increases the renal excretion of uric acid.","indications":["COVID-19"],"catalyst":""},{"name":"AT-527 fasted","genericName":"AT-527 fasted","slug":"at-527-fasted","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"AT-527 fed","genericName":"AT-527 fed","slug":"at-527-fed","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"AT-527 single dose","genericName":"AT-527 single dose","slug":"at-527-single-dose","phase":"phase_1","mechanism":"AT-527 is a nucleoside analog that inhibits viral RNA-dependent RNA polymerase, thereby blocking viral replication.","indications":["Treatment of SARS-CoV-2 infection"],"catalyst":""},{"name":"Bemnifosbuvir (BEM)","genericName":"Bemnifosbuvir (BEM)","slug":"bemnifosbuvir-bem","phase":"phase_3","mechanism":"Bemnifosbuvir is a nucleoside analog that inhibits viral RNA-dependent RNA polymerase, blocking replication of RNA viruses.","indications":["COVID-19 (SARS-CoV-2 infection)","Respiratory viral infections"],"catalyst":""},{"name":"Bemnifosbuvir-Ruzasvir","genericName":"Bemnifosbuvir-Ruzasvir","slug":"bemnifosbuvir-ruzasvir","phase":"phase_3","mechanism":"Bemnifosbuvir is a nucleoside analog that inhibits hepatitis C virus (HCV) RNA-dependent RNA polymerase, while ruzasvir is an NS5A inhibitor that blocks viral protein function and replication.","indications":["Chronic hepatitis C virus (HCV) infection, genotype 1-6"],"catalyst":""}],"recentEvents":[{"date":"2023-02-14","type":"regulatory","headline":"Atea Pharmaceuticals Announces FDA Fast Track Designation for AT-527 for the Treatment of COVID-19","summary":"Atea Pharmaceuticals announced that the FDA has granted Fast Track designation to AT-527 for the treatment of COVID-19.","drugName":"AT-527","sentiment":"positive"},{"date":"2022-11-15","type":"earnings","headline":"Atea Pharmaceuticals Reports Third Quarter 2022 Financial Results","summary":"Atea Pharmaceuticals reported its third quarter 2022 financial results, highlighting progress in its pipeline and business development efforts.","drugName":"","sentiment":"neutral"},{"date":"2022-08-09","type":"deal","headline":"Atea Pharmaceuticals Announces Collaboration with Merck to Develop AT-527 for the Treatment of COVID-19","summary":"Atea Pharmaceuticals announced a collaboration with Merck to develop AT-527 for the treatment of COVID-19.","drugName":"","sentiment":"positive"}],"realNews":[{"url":"https://news.google.com/rss/articles/CBMitAFBVV95cUxPYWVsLU8tdGtwb3lSd2plY1hxUHM3aG9wSGptX1Q1akhMTEpXZm1QNndYUVg4dnVjNDZ0Wm9FM1dNTGxtd0szUm9fTW52ZmQtWXZodWI3SUxaQjhSV19uemhNaGNIcGZBTFhKQWRZcDVxYlBfQkNTeUJFcVRMYTVPdUJwS3ZpQ3JPbGxHc0xxRXVtUTZuNUNYQjZ0NnUtc3dGdXI2aGpTS01CeEtkc09BY3dwU2c?oc=5","date":"2026-04-01","type":"pipeline","source":"Kalkine Media","summary":"Atea Pharmaceuticals (NASDAQ:AVIR) Trading Surge Draws Market Attention - Kalkine Media","headline":"Atea Pharmaceuticals (NASDAQ:AVIR) Trading Surge Draws Market Attention","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMibkFVX3lxTE5VT0tINjBIM1hMVkE4MmxHbHc5d0JhcUd0eUlmV3VrQ3k3Q1A4ckNESzNlUnZvVmwyVzV3MDg3TzF5MkZEYkdxTjZGRzhJbmxleEdka01MOGdEanhKb1NueWs0WWRUcmc1NDd0VHNB?oc=5","date":"2026-03-22","type":"pipeline","source":"Stock Titan","summary":"If You Invested $1,000 in Atea Pharmaceuticals, Inc. (AVIR) - Stock Titan","headline":"If You Invested $1,000 in Atea Pharmaceuticals, Inc. (AVIR)","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiwwFBVV95cUxPaGR3bnlEN09LUkpUcF9VYWZZeWUxdlc3WjlsWW5CMnFtZ3VkWjhmRXkxNmZhV2Z1SGpENC1nTEs3eEFaaDhzRjZhb1B4OFlZMmVhcnduMF84N1Z6UjJCNnU5LTFIbzBocVFCaUxxbkloaXV5cWF4NFhWQ3BQVUlHaE9DU18zT2lQMEhTUUFtcDJralF6VzJoRWVqMHFza2hmeGJqWWNGVE1kazFwazhWNnJhV3I2eXliZk5fYXZMQ3dWSGs?oc=5","date":"2026-03-05","type":"earnings","source":"The Globe and Mail","summary":"Atea Pharma (AVIR) Earnings Call Transcript - The Globe and Mail","headline":"Atea Pharma (AVIR) Earnings Call Transcript","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMitAFBVV95cUxNSVF5dzlTTHpXMEFqMVk5ZEJrMktOREZ3ajMzXzhxS2dDLUpUYkhBSWRyOWtzSGh6SFl2RldMSi1TcVBRY1ZxM2xTSDZfbjd1OTIyRlYxbnFjRk9XUVJVWk12TWpJUWhreHREdjc2TW1VUkJWTmZtbmpBZTZxaVF5QnZoT0Yya0pfenNTR0tpQ0xMRm1WM3g0QnBKanlvcnN2eXhHNXk5YzQ3VTdUdFZwc1RHQ0Y?oc=5","date":"2026-03-05","type":"earnings","source":"TradingView","summary":"Atea Pharmaceuticals 10-K: $0 Revenue, $(158.3)M Net Loss - TradingView","headline":"Atea Pharmaceuticals 10-K: $0 Revenue, $(158.3)M Net Loss","sentiment":"neutral"},{"date":"2026-03-05","type":"earnings","source":"SEC EDGAR","summary":"10-K filed with SEC: 10-K","headline":"Annual Report (10-K) Filed","sentiment":"neutral"},{"date":"2026-03-05","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMirAJBVV95cUxNWTZaSXJnbFd6Q09KaHdnTl9ycUt4U1EyZC1DZ0psdlh2eEdzdzBfNExnNm1WX3NfeU9melp5bnpGRlQxbkVkcGY4QnJWdndPMVd6d093cERFSFdCZElUaG1IYzBTZHhnVHZGTWJtdTB4Y0dyNWpGUzRXYXQxOHpibV9JZkk3d1U2bFFwT29IT1hIRUhvNU8yMXY5UlR4SXpsUE5hbXhLLWFMdDlQSU1QUTlVMXF6cThHZFhPSGxRNzVCUEU5X1dkSWVpWFFiMVdoQ1p6eDkxLV83YlVOUk14cFhySk5QajVLZGZKVE1VbUlLbDZEaWl6WGp2eHhQcmltTU1wcjVuVHlhemNtdVJkbmNzdUc2ZWU0cVUzRHZxeTMtcUhtM2x6a2tnTHI?oc=5","date":"2026-02-26","type":"earnings","source":"globenewswire.com","summary":"Atea Pharmaceuticals to Host Fourth Quarter and Full Year - globenewswire.com","headline":"Atea Pharmaceuticals to Host Fourth Quarter and Full Year","sentiment":"neutral"},{"date":"2026-01-08","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiwgFBVV95cUxOTEVJZVB3UjlXYmxtdXhZWFpTOXJHWXpGRHNObkdjUl9nRUxVVUxTU21ZWHNLU0dvTGtNVjdLbkc0ZHZ2WUYtNjQ4c29iNjI5Q1V1LUY5cTY0dEI2SzdJOUtKM2tLd25iZS0ycC1JSnBDdE1pN3lJRnhuS1hEOWhnMzI5TFU4VU15UzNXNDFTdnBLUnIwMGpOYUxscW4zSFRTbmNkeF9BSVNuLU1VUTV3ODVvem5mOW8xQ3hfRkluNzdfdw?oc=5","date":"2025-12-23","type":"trial","source":"Seeking Alpha","summary":"Atea Pharmaceuticals: Potential Best-In-Class HCV Cure With Pivotal Readouts In 2026 - Seeking Alpha","headline":"Atea Pharmaceuticals: Potential Best-In-Class HCV Cure With Pivotal Readouts In 2026","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMipwFBVV95cUxPYWpwRWxDZ1dQUklpTC1BbzVjcW1ZNXlvY2hkLW02VHVIWmhvWDEwZF8tUTlJak1PbkRMVTVXaTF6QXRWT1NTcUZ5QnYtdUhHcTUzV0t0UHZMZ2JveGQ1Y0I4UDFvZEUtUDZoZDdXZDR5YWlOZzkwUWpOZzNmNnZxRDUzclY5TlppUmEyMTV0UDM3Y0FWWS1yQm1VYmJrTXAtZ1dfUWcwVQ?oc=5","date":"2025-12-23","type":"pipeline","source":"RTTNews","summary":"Is Atea Pharma Moving BEYOND The Virus And FORWARD To Breakthroughs? - RTTNews","headline":"Is Atea Pharma Moving BEYOND The Virus And FORWARD To Breakthroughs?","sentiment":"neutral"},{"date":"2025-11-12","type":"earnings","source":"SEC EDGAR","summary":"10-Q filed with SEC: 10-Q","headline":"Quarterly Report (10-Q) Filed","sentiment":"neutral"},{"date":"2025-11-12","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"url":"https://news.google.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?oc=5","date":"2025-09-19","type":"deal","source":"simplywall.st","summary":"Insiders Enjoy US$723k Return After Buying Atea Pharmaceuticals Stock - simplywall.st","headline":"Insiders Enjoy US$723k Return After Buying Atea Pharmaceuticals Stock","sentiment":"neutral"},{"date":"2025-08-07","type":"earnings","source":"SEC EDGAR","summary":"10-Q filed with SEC: 10-Q","headline":"Quarterly Report (10-Q) Filed","sentiment":"neutral"},{"date":"2025-08-07","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"}],"patents":[{"drugName":"AT-527","drugSlug":"at-527","patentNumber":"","type":"Patent Cliff","expiryDate":"2030-06-01","territory":"US","annualRevenue":0}],"drugCount":8,"phaseCounts":{"phase_1":6,"phase_3":2},"enrichmentLevel":3,"visitCount":1,"keyCompetitors":["Gilead Sciences","Merck & Co.","Vertex Pharmaceuticals"],"therapeuticFocus":["Antiviral Therapies"],"financials":{"source":"sec_edgar","revenue":351367000,"revenuePeriod":"2021-12-31","revenueHistory":[{"value":351367000,"period":"2021-12-31"},{"value":351367000,"period":"2021-12-31"},{"value":48633000,"period":"2020-12-31"},{"value":48633000,"period":"2020-12-31"},{"value":48633000,"period":"2020-12-31"}],"grossProfit":null,"grossProfitHistory":[],"rdSpend":148024000,"rdSpendHistory":[],"sgaSpend":null,"operatingIncome":null,"operatingIncomeHistory":[],"netIncome":-158349000,"netIncomeHistory":[],"eps":null,"epsHistory":[],"cash":null,"cashHistory":[],"totalAssets":315218000,"totalLiabilities":null,"totalDebt":null,"equity":null,"operatingCashflow":null,"operatingCashflowHistory":[],"capex":null,"capexHistory":[],"freeCashflow":null,"dividendsPaid":null,"buybacks":null,"employees":null,"segmentRevenue":[],"geographicRevenue":[],"ciks":null,"lastFiledAt":null},"yahoo":null}